Correction of cancer anemia - Impact on disease course, prognosis and treatment efficacy, particularly for patients undergoing radiotherapy

Onkologie

Volumn 24, Issue 5, 2001, Pages 450-454

  Henke, M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Anemia; Cancer treatment; Erythropoietin

Indexed keywords

CYTOSTATIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; HEMOGLOBIN DETERMINATION; HUMAN; HYPOXEMIA; IMMUNE DEFICIENCY; INFECTION RISK; MEDICAL SPECIALIST; PROGNOSIS; QUALITY OF LIFE; RADIATION RESPONSE; RADIOSENSITIVITY; SHORT SURVEY; TISSUE OXYGENATION; TREATMENT OUTCOME; TUMOR GROWTH;

ANEMIA; CELL HYPOXIA; CLINICAL TRIALS; ERYTHROPOIETIN, RECOMBINANT; HUMANS; NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0034761737     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055125     Document Type: Short Survey

References (64)

1. Erythropoietin in radiation oncology - A review. 1. International conference, Freiburg, June 11-12, 1999
2. Anemia in patients with neoplastic disease
3. The significance of anemia in clinical radiation therapy
4. The anemia of chronic disorders
5. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice
6. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys
7. Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon
8. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon
9. A motif within the 5′non-coding regions of acute phase mRNAs mediates ferritin translation by IL-1 and may contribute to the anemia of chronic disease
10. New approaches to the treatment of cancer related anemia, a panel discussion
11. Pathogenesis and treatment of the anemia of chronic disease
12. Serum levels of erythropoietin in anemia associated with chronic infection, malignancy and primary hematopoietic disease
13. Decreased erythropoietin response in patients with the anemia of cancer
14. Sensitization of hypoxic tumor cells clinical experience
15. Radiotherapy and anaemia the clinical experience
16. Erythropoietin for patients undergoing radiotherapy. The Freiburg experience
17. Association of hemoglobin levels before and during radiotherapy with prognosis in uterine cervix cancer
18. Factors affecting survival in over 500 patients with stage II carcinoma of the cervix
19. Pretreatment prognostic factors in carcinoma of the uterine cervix: A multivariable analysis of the effect of age, stage, histology and blood counts on survival
20. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: Results of a retrospective study of 386 patients
21. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy
22. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin
23. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue
24. Quality of life and anemia: The nephrology experience
25. Quality of life and hematocrit level
26. Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: A randomized prospective study
27. Modification of tumour blood flow - A review
28. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas
29. 2 tension measurement
30. On the effet of anaemia on the reactions of the skin and on tumours to radium exposure
31. Blood hemoglobin level may affect radiosensitivity - Preliminary results on acutely reacting normal tissues
32. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy
33. Nine decades of radiobiology: Is radiation therapy any better for it?
34. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma
35. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix
36. The influence of tumor hypoxia on malignant progression
37. Hypoxia facilitates tumour cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of cell viability
38. Hypoxia and drug resistance
39. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect
40. The influence of anemia on the results of radiotherapy in carcinoma of the cervix
41. Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85
42. Transfusion medicine. First of two parts - Blood transfusion
43. Effect of blood transfusions on subsequent kidney transplants
44. Effect of allogeneic blood transfusion on solid tumor growth and pulmonary metastases in mice
45. Expression of the erythropoietin gene
46. Erythropoietin and the kidney
47. Erythropoietin and the control of red blood cell production
48. Three stages of erythropoietic progenitor cell differentiation distinguished by a number of physical and biological properties
49. The application of recombinant erythropoietin in anemic patients with cancer
50. Anemia in cancer patients
51. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration
52. Erythropoietin for anemia in cancer patients
53. Erythropoietin increases hemoglobin in cancer patients during radiation therapy
54. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer
55. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: Final report of a randomized, open-labeled, phase II trial
56. Erythropoietin for patients undergoing radiotherapy: A pilot study
57. Effect of the administration of recombinant human erythropoietin in patients with pelvic malignancies during radiotherapy
58. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx
59. Effect of cancer fatigue
60. Changing patterns of care in the management of anemia
61. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy
62. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
63. Quality-of-life benefit in chemotherapy patients treated with epoetin alpha is independent of disease response or tumor type: Results from a prospective community oncology study